(19)
(11) EP 2 698 386 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.02.2018 Bulletin 2018/06

(45) Mention of the grant of the patent:
20.12.2017 Bulletin 2017/51

(21) Application number: 12770896.4

(22) Date of filing: 02.04.2012
(51) International Patent Classification (IPC): 
C07K 19/00(2006.01)
A61P 37/06(2006.01)
C07K 16/18(2006.01)
C12N 15/09(2006.01)
A61K 38/00(2006.01)
C07K 14/47(2006.01)
C12P 21/02(2006.01)
C07K 14/705(2006.01)
(86) International application number:
PCT/JP2012/058912
(87) International publication number:
WO 2012/141026 (18.10.2012 Gazette 2012/42)

(54)

FUSION PROTEIN

FUSIONSPROTEIN

PROTÉINE DE FUSION


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 13.04.2011 JP 2011088762

(43) Date of publication of application:
19.02.2014 Bulletin 2014/08

(73) Proprietor: Nihon Pharmaceutical Co., Ltd.
Chuo-ku, Tokyo 104-0044 (JP)

(72) Inventors:
  • KOGURE, Takahisa
    Chiba 286-0825 (JP)
  • NAKAJIMA, Kenji
    Osaka 598-0061 (JP)
  • HOMMA, Masayuki
    Narita-shi Chiba 286-0825 (JP)

(74) Representative: Patentanwälte Ruff, Wilhelm, Beier, Dauster & Partner mbB 
Kronenstraße 30
70174 Stuttgart
70174 Stuttgart (DE)


(56) References cited: : 
WO-A1-2011/013470
WO-A2-2004/110472
JP-A- 9 077 800
JP-A- 2011 032 188
WO-A2-03/068822
DE-A1- 10 160 248
JP-A- 2007 505 643
   
  • CHANG T ET AL: "Selective recognition and elimination of nicotinic acetylcholine receptor-reactive B cells by a recombinant fusion protein AChR-Fc in myasthenia gravis in vitro", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 227, no. 1-2, 8 October 2010 (2010-10-08), pages 35-43, XP027288214, ISSN: 0165-5728 [retrieved on 2010-08-19]
  • ZOCHER M ET AL: "SPECIFIC DEPLETION OF AUTOREACTIVE B LYMPHOCYTES BY A RECOMBINANT FUSION PROTEIN IN VITRO AND IN VIVO", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 15, no. 7, 1 July 2003 (2003-07-01), pages 789-796, XP001155918, ISSN: 0953-8178, DOI: 10.1093/INTIMM/DXG076
  • ZOCHER M. ET AL.: 'Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo' INT. IMMUNOL. vol. 15, no. 7, 2003, pages 789 - 796, XP001155918
  • TSOULOUFIS T. ET AL.: 'Reconstitution of conformationally dependent epitopes on the N-terminal extracellular domain of the human muscle acetylcholine receptor alpha subunit expressed in Escherichia coli: implications for myasthenia gravis therapeutic approaches' INT. IMMUNOL. vol. 12, no. 9, 2000, pages 1255 - 1265, XP008148987
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).